Evidence map›Paper›PMID 41123429›Full record

ArticleeLife2025

Stabilisation of HIF signalling in the mouse epicardium extends embryonic potential and neonatal heart regeneration.

Elisabetta Gamen, Eleanor L Price, Daniela Pezzolla, Carla De Villiers, Mala Gunadasa-Rohling, Adam B Lokman, Maria-Alexa Cosma, Judith Sayers, Carolina Roque Silva, Rafik Salama and 7 more

Abstract read
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Elisabetta GamenInstitute of Developmental and Regenerative Medicine (IDRM), Oxford, United Kingdom.
Eleanor L PriceBurdon-Sanderson Cardiac Science Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United Kingdom.
Daniela PezzollaDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.ORCID https://orcid.org/0000-0001-8060-3706
Carla De VilliersInstitute of Developmental and Regenerative Medicine (IDRM), Oxford, United Kingdom.
Mala Gunadasa-RohlingInstitute of Developmental and Regenerative Medicine (IDRM), Oxford, United Kingdom.
Adam B LokmanInstitute of Developmental and Regenerative Medicine (IDRM), Oxford, United Kingdom.ORCID https://orcid.org/0000-0002-8717-4550
Maria-Alexa CosmaInstitute of Developmental and Regenerative Medicine (IDRM), Oxford, United Kingdom.
Judith SayersInstitute of Developmental and Regenerative Medicine (IDRM), Oxford, United Kingdom.
Carolina Roque SilvaInstitute of Developmental and Regenerative Medicine (IDRM), Oxford, United Kingdom.
Rafik SalamaNDM Research Building, University of Oxford, Oxford, United Kingdom.
David Robert MoleNDM Research Building, University of Oxford, Oxford, United Kingdom.
Tammie BishopBurdon-Sanderson Cardiac Science Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United Kingdom.
Chris W PughTarget Discovery Institute, University of Oxford, Oxford, United Kingdom.
Robin P ChoudhuryDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
Carolyn A CarrBurdon-Sanderson Cardiac Science Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United Kingdom.
Joaquim Miguel Vieira *School of Cardiovascular and Metabolic Medicine and Sciences, British Heart Foundation Centre of Research Excellence, King's College London, London, United Kingdom.ORCID https://orcid.org/0000-0003-2023-6304
Paul R Riley *Institute of Developmental and Regenerative Medicine (IDRM), Oxford, United Kingdom.ORCID https://orcid.org/0000-0002-9862-7332

Funding

British Heart Foundation CH/11/1/28798British Heart Foundation FS/19/31/34158British Heart Foundation RG/18/33532British Heart Foundation RM/17/2/33380Wellcome Trust
6 · The paper itself

Abstract

In humans, new-born infants can regenerate their heart during early life. This is modelled in the mouse, where regenerative capacity is maintained for the first week after birth but lost thereafter. Reactivation of this process holds great therapeutic potential; however, the molecular pathways that might be targeted to extend neonatal regeneration remain elusive. Here, we explored a role for hypoxia and HIF signalling on the regulation of epicardial activity in the developing mouse heart and in modulating the response to injury. Hypoxic regions were found in the epicardium from mid-gestation, associating with HIF-1α and HIF-2α, and expression of the epicardial master regulator Wilms' tumour 1 (WT1). Epicardial deletion of

Indexed as

Basic Helix-Loop-Helix ProteinsHeartHypoxia-Inducible Factor 1, alpha SubunitPericardiumRegenerationSignal TransductionAnimalsAnimals, NewbornEndothelial PAS Domain-Containing Protein 1Hypoxia-Inducible Factor-Proline DioxygenasesMiceWT1 ProteinsBasic Helix-Loop-Helix ProteinsEgln1 protein, mouseEndothelial PAS Domain-Containing Protein 1Hif1a protein, mouseHypoxia-Inducible Factor 1, alpha SubunitHypoxia-Inducible Factor-Proline DioxygenasesWT1 protein, mouseWT1 Proteinsepicardiumhearthypoxiamouseregenerationregenerative medicinestem cells

Identifiers

PMID41123429
PMCPMC12543327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.